Phani Ashok Attaluri, MD
Gastroenterology · Olathe, KSNPI 1417066499
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $846,351 of the $957,072 with a category attached, or 88.4%. 34 manufacturers reported payments, led by Sanofi at 34.4% of the total. Among gastroenterology clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,032 payments — averaging $927.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$329K
- Regeneron Healthcare Solutions, Inc.$318K
- AbbVie$115K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$98K
- Merck$26K
- Ardelyx, Inc.$16K
- plus $55K from 28 others
What the payments were for
- Consulting fees$29,3453%
- Speaking & faculty fees$846,35188%
- Travel & lodging$63,3817%
- Food & beverage$17,9472%
- Education$480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 156 | $329,036 |
| Regeneron Healthcare Solutions, Inc. | 176 | $317,937 |
| AbbVie(2 entities) | 250 | $114,761 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 133 | $97,876 |
| Merck | 37 | $26,069 |
| Ardelyx, Inc. | 29 | $15,914 |
| E.r. Squibb & Sons, L.L.C. | 10 | $15,384 |
| Ironwood Pharmaceuticals, Inc | 13 | $10,166 |
| Takeda Pharmaceuticals U.S.A., Inc. | 49 | $9,273 |
| Pfizer | 29 | $8,974 |
| Bristol Myers Squibb | 23 | $3,272 |
| Alfasigma USA, Inc. | 7 | $2,029 |
| AstraZeneca | 2 | $1,976 |
| Boston Scientific | 2 | $1,234 |
| Johnson & Johnson | 67 | $928 |
| Covidien LP | 1 | $534 |
| Janssen Scientific Affairs, LLC | 1 | $525 |
| Mallinckrodt Hospital Products Inc. | 4 | $202 |
| Medtronic | 2 | $176 |
| Nestle Healthcare Nutrition Inc. | 7 | $123 |
| Aimmune Therapeutics, Inc. | 4 | $114 |
| Intercept Pharmaceuticals, Inc. | 7 | $114 |
| QOL Medical, LLC | 4 | $91 |
| Lilly USA, LLC | 3 | $82 |
| Celltrion USA Inc. | 3 | $69 |
| Madrigal Pharmaceuticals | 2 | $43 |
| Gilead | 2 | $31 |
| Romark Laboratories, LC | 2 | $29 |
| Braintree Laboratories, Inc. | 1 | $24 |
| Shionogi Inc | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 2 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$957,072 in reported general payments places this provider in the 95th percentile of 98 gastroenterology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 63 | $242,140 |
| RinvoqUpadacitinib | 20 | $129,291 |
| LinzessLinaclotide | 86 | $62,009 |
| XifaxanRifaximin | 12 | $37,213 |
| Mesalamine | 24 | $15,961 |
| Colestipol Hcl | 61 | $8,860 |
| MovantikNaloxegol Oxalate | 17 | $8,513 |
| Pantoprazole Sodium | 548 | $5,704 |
| CholestyramineCholestyramine (With Sugar) | 62 | $4,429 |
| Dexlansoprazole DrDexlansoprazole | 11 | $4,292 |
| Lubiprostone | 36 | $2,821 |
| Famotidine | 157 | $2,135 |
| Mesalamine ErMesalamine | 16 | $2,052 |
| Omeprazole | 147 | $1,994 |
| Sucralfate | 58 | $1,292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Rinvoq, Linzess | $114,761 | $433,440169 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $97,876 | $37,21312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 98 gastroenterology providers in Kansas.
Other gastroenterology in Olathe
- Mohammad TitiOlathe$2K
- Stella QuiasonOlathe$1K
- Ryan TaylorKansas City$241K
- Winston DunnKansas City$169K
- Francis DaileyLeawood$82K
- Rashmi TadiparthiKansas City$60K
- Prateek SharmaKansas City$47K
- Erica DaileyOverland Park$33K
- Ervin EakerShawnee$11K
- Alka HudsonLawrence$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.